As of November 7, 2026, Protagonist Therapeutics, Inc is a publicly traded company (Nasdaq: PTGX); its largest reported holder is BlackRock, with 15.2% on Schedule 13G/A of October 27, 2026, then Farallon Capital Management, L.L.C. (9.99%). The largest insider holding is Dinesh V. Ph D. Patel, the chief executive and president, with 522,968 shares (0.80% of shares outstanding), per Form 4 of September 10, 2026 (Schedule 13G/A, October 27, 2026).
Is this your company?
About to sign with, pay or invest in Protagonist Therapeutics, Inc? See the free Snapshot first.
Free to see. No signup.
Is Protagonist Therapeutics, Inc a real, registered company?
- Protagonist Therapeutics, Inc files with the SEC under CIK 1377121 (its SEC filings).
- Its shares are listed under the ticker PTGX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Newark, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Protagonist Therapeutics, Inc in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Protagonist Therapeutics, Inc's owners and officers?
Protagonist Therapeutics, Inc: incorporated in Delaware; business address in Newark, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-27 | Blackrock, Inc. | 15.2% |
| Schedule 13G/A, 2026-08-13 | Farallon Capital Management, L.L.C. | 9.99% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 5.2% |
| Schedule 13G, 2026-05-12 | State Street Corporation | 4.9% |
| Schedule 13G, 2026-04-30 | Vanguard Capital Management | 5.09% |
| Schedule 13G, 2026-04-29 | Vanguard Portfolio Management | 5.53% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Rtw Investments, LP | 8.1% |
| Schedule 13G, 2026-02-10 | Wellington Management Group LLP | 5.1% |
| Schedule 13G/A, 2026-02-06 | Dapice Joshua J. | 9.99% |
| Schedule 13G/A, 2026-01-30 | The Vanguard Group | 8.65% |
| Schedule 13G/A, 2025-11-14 | Bvf Partners L P/Il | 4.1% |
Questions about who owns Protagonist Therapeutics, Inc
Who owns Protagonist Therapeutics, Inc?
On this page, 8 holders' latest ownership filings report 5% or more of Protagonist Therapeutics, Inc: Blackrock, Inc. (15.2%, Schedule 13G/A, filed 2026-10-27), Farallon Capital Management, L.L.C. (9.99%, Schedule 13G/A, filed 2026-08-13), Dapice Joshua J. (9.99%, Schedule 13G/A, filed 2026-02-06), Rtw Investments, LP (8.1%, Schedule 13G/A, filed 2026-02-17) and Vanguard Portfolio Management (5.53%, Schedule 13G, filed 2026-04-29); 3 more are listed above.
Who are the largest shareholders of Protagonist Therapeutics, Inc?
By the share each holder's latest filing reports, the largest holders of Protagonist Therapeutics, Inc on this page are Blackrock, Inc. (15.2%), Farallon Capital Management, L.L.C. (9.99%) and Dapice Joshua J. (9.99%).
When did Blackrock, Inc. buy into Protagonist Therapeutics, Inc?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2026-10-27, reporting 15.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Protagonist Therapeutics, Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Protagonist Therapeutics, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Protagonist Therapeutics, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Protagonist Therapeutics, Inc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 522,968 shares (0.80% of shares outstanding) (Form 4, 2026-09-10).
- , the chief development officer: 267,433 shares (0.41% of shares outstanding) (Form 4, 2024-11-27).
- , the chief medical officer: 84,115 shares (0.13% of shares outstanding) (Form 4, 2026-03-27).
- , a director: 60,845 shares (0.09% of shares outstanding) (Form 4, 2026-03-27).
- , the chief financial officer: 59,003 shares (0.09% of shares outstanding) (Form 4, 2026-10-02).
Shares outstanding: 65,270,114 as of 2026-10-31, from the company's latest SEC cover page.
How much has Protagonist Therapeutics, Inc raised?
No fundraising or offering filing from Protagonist Therapeutics, Inc is on file with us.
Keep reading
More on Protagonist Therapeutics, Inc and the records around it.
Protagonist Therapeutics, Inc elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/protagonist-therapeutics